首页|倍他司汀联合氢溴酸山莨菪碱治疗眩晕症的疗效

倍他司汀联合氢溴酸山莨菪碱治疗眩晕症的疗效

扫码查看
目的 研究倍他司汀联合氢溴酸山莨菪碱治疗眩晕症患者的疗效、安全性以及对患者血流动力学、血清血小板活化因子(platelet activated factor,PAF)和血栓素B2(thromboxane B2,TXB2)的影响。方法 将80例眩晕症患者用随机数字表法分为倍他司汀组和对照组,各40例。对照组采用氢溴酸山莨菪碱治疗,倍他司汀组在对照组治疗的基础上加用倍他司汀治疗,治疗周期为14 d。治疗后通过眩晕症状评分简化量表(vertigo symptom score-short form,VSS-SF)和眩晕残障程度评定量表(dizziness handicap inventory,DHI)评估患者的眩晕程度;通过经颅多普勒(transcranial doppler,TCD)结果评价患者左椎动脉、右椎动脉和椎基底动脉的血流情况;测定患者血清PAF和TXB2水平;统计治疗后总有效率;观察2组患者不良反应(呕吐、过敏反应、睡眠障碍、肝功能异常和凝血功能异常)的发生情况。结果 治疗后,倍他司汀组患者的总有效率高于对照组(P<0。05);倍他司汀组的VSS-SF、DHI量表评分均低于对照组(P<0。05),患者左椎动脉、右椎动脉和椎基底动脉血流情况均优于对照组(P<0。05),患者PAF、TXB2水平均低于对照组(P<0。05);2组不良反应发生率比较差异无统计学意义。结论 倍他司汀联合氢溴酸山莨菪碱治疗眩晕症有较好的临床效果,可以改善患者的眩晕症状及眩晕程度,降低患者的炎性因子水平,对于患者脑部血流动力学有较好的改善作用。
Efficacy of betahistine combined with anisodamine hydrobromide in the treatment of vertigo
Objective To study the efficacy and safety of betahistine combined with anisodamine hydrobromide in the treatment of patients with vertigo and influence on hemodynamics,serum platelet activating factor(PAF)and thromboxane B2(TXB2).Methods 80 patients with vertigo were divided into betahistine group and control group according to random number table method,with 40 cases in each group.The control group was treated with anisodamine hydrobromide,and the betahistine group was additionally given betahistine on the basis of the control group.The both groups were treated for 14 days.After treatment,the vertigo degree was assessed by vertigo symptom score-short form(VSS-SF)and vertigo dizziness handicap inventory(DHI).Transcranial doppler(TCD)was used to evaluate the blood flow status of the left vertebral artery,right vertebral artery and vertebrobasilar artery.The levels of serum PAF and TXB2 were determined in both groups.The total effective rate after treatment was counted and the adverse reactions(vomiting,allergic reaction,sleep disorder,abnormal liver function,or abnormal coagulation function)were observed in the 2 groups.Results The total effective rate in betahistine group after treatment was higher compared with that in control group(P<0.05).After treatment,the scores of VSS-SF and DHI in betahistine group were lower than those in control group(P<0.05),and the blood flow status of left vertebral artery,right vertebral artery and vertebrobasilar artery were better than those in control group(P<0.05),and the levels of PAF and TXB2 were lower when compared with control group(P<0.05).There was no statistically significant difference in the incidence rates of adverse reactions between the 2 groups.Conclusion Betahistine combined with anisodamine hydrobromide has a good clinical effect in the treatment of vertigo.The combination can improve the vertigo symptom and vertigo degree,reduce the levels of inflammatory factors,and has a good improvement effect on cerebral hemodynamics.

betahistineanisodamine hydrobromidevertigoplatelet activating factorthromboxane B2

方小龙、花杰、刘曙光、石芳

展开 >

南京鼓楼医院集团安庆市石化医院神经内科,安庆 246000

倍他司汀 氢溴酸山莨菪碱 眩晕症 血小板聚集因子 血栓素B2

2022年度安徽省卫生健康科研项目

AHWJ2022c035

2024

西北药学杂志
西安交通大学,陕西省药学会

西北药学杂志

CSTPCD
影响因子:0.912
ISSN:1004-2407
年,卷(期):2024.39(4)